<DOC>
	<DOCNO>NCT02200770</DOCNO>
	<brief_summary>To compare efficacy MEDI-551 versus placebo reduce risk NMO/NMOSD attack subject NMO/NMOSD .</brief_summary>
	<brief_title>A Double-masked , Placebo-controlled Study With Open Label Period Evaluate MEDI-551 Neuromyelitis Optica Neuromyelitis Optica Spectrum Disorders</brief_title>
	<detailed_description>MEDI-551 genetically engineer humanized monoclonal antibody bind B cell specific surface antigen CD19 result depletion B cell . CD19 positive ( CD19+ ) B-lineage plasmablast responsible production autoantibody AQP4 channel protein . The main objective study determine whether MEDI-551 compare placebo decrease risk attack subject NMO/NMOSD . This multicenter , multinational , randomize , double-masked , placebo control study open-label extension period evaluate efficacy safety intravenous ( IV ) MEDI-551 adult subject NMO/NMOSD . After screen period , eligible subject enter randomized-controlled period ( RCP ) maximum 197 day randomize 3:1 ratio receive either IV MEDI-551 placebo . NMO/NMOSD attack evaluate investigator confirm attack criterion independent Adjudication Committee ( AC ) . Subjects attack confirm AC give option enroll open label period ( OLP ) MEDI-551 treatment . Subjects complete RCP without experience attack give option enroll OLP MEDI-551 treatment . The OLP continue minimum 1 year maximum 3 year last subject enter OLP . All subject discontinue RCP OLP continue Safety Follow-up total 12 month last dose evaluate long-term safety investigational product .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>1 . Men woman 18 year old diagnosis NMO/NMOSD 2 . Confirmation NMO/NMOSD status : 1 . AQP4IgG seropositive NMO/NMOSD least one attack require rescue therapy last year two attack require rescue therapy last 2 year 2 . AQP4IgG seronegative NMO least one attack require rescue therapy last year two attack require rescue therapy last 2 year 3 . Able willing give write informed consent comply requirement study protocol . 4 . EDSS &lt; = 7.5 ( 8 special circumstance ) 5 . Men woman reproductive potential must agree use highly effective method birth control screen 6 month final dose investigational product . 1 . Lactating pregnant female 2 . Treatment investigational agent within 4 week screen 3 . Known history severe allergy reaction component investigational product formulation history anaphylaxis follow biologic therapy . 4 . Known active severe bacterial , viral , infection major episode infection require hospitalization . 5 . History alcohol , drug , chemical abuse , recent history abuse &lt; 1 year prior randomization 6 . Receipt following time prior randomization : 1 . Alemtuzumab 2 . Total lymphoid irradiation 3 . Bone marrow transplant 4 . Tcell vaccination therapy 7 . Receipt rituximab experimental Bcell deplete agent within 6 month prior screen Bcells low limit normal . 8 . Receipt IVIG within 1 month prior randomization . 9 . Receipt follow within 3 month prior randomization : 1 . Natalizumab ( TysabriÂ® ) b . 2 . Cyclosporin 3 . Methotrexate 4 . Mitoxantrone 5 . Cyclophosphamide 6 . Tocilizumab 7 . Eculizumab 10 . History Hepatitis B and/or Hepatitis C ( Hep B/C screen ) 11 . Known history primary immunodeficiency ( congenital acquire ) underlie condition human immunodeficiency virus ( HIV ) infection 12 . History malignancy , apart squamous cell basal cell carcinoma skin treat documented success curative therapy &gt; 3 month prior randomization 13 . Any concomitant disease NMO/NMOSD require treatment oral intravenous steroid dose 20 mg day 21 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>NMO , NMOSD , Neuromyelitis Optica , Neuromyelitis Optica Spectrum Disorders , autoimmune , demyelination , MEDI-551 , monoclonal antibody , Devic 's syndrome , B-cell</keyword>
</DOC>